Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0

Indoleamine 2,3-dioxygenase (IDO1) is a key regulator of immune suppression by catalyzing the oxidation of L-tryptophan. IDO1 expression has been related to poor prognosis in several cancers and to resistance to checkpoint immunotherapies. We describe the characterization of a novel small molecule I...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Yvonne Grobben, Jos de Man, Antoon M. van Doornmalen, Michelle Muller, Nicole Willemsen-Seegers, Diep Vu-Pham, Winfried R. Mulder, Martine B. W. Prinsen, Joeri de Wit, Jan Gerard Sterrenburg, Freek van Cauter, Judith E. den Ouden, Anne M. van Altena, Leon F. Massuger, Joost C. M. Uitdehaag, Rogier C. Buijsman, Guido J. R. Zaman
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-01-01
Subjects:	indoleamine 2,3-dioxygenase cancer immunotherapy immunosuppression tryptophan kynurenine syngeneic mouse model
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2020.609490/full